AC Immune SA (ACIU)
NASDAQ: ACIUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACIU stock chart
Technical analysisKey statistics
All statistics- Market cap
- $193.88M
- Forward P/E
- 2.84
- EPS (TTM)
- -$0.44
- Dividend yield
- None
- 52-week range
- 1.93 – 3.90
- Day range
- 1.93 – 2.15
- Volume / Avg
- 297.66K / 198.81K
- Beta
- —
- Shares outstanding
- 99.43M
52-week range
ACIU stock today
AC Immune SA (ACIU) closed at $1.95 on Nov 20, down 8.45% (-$0.18), versus the S&P 500's 3.70% decline. At this level, ACIU sits near the bottom of its 52-week range of $1.93 to $3.90: 50.0% below the high, set on Jan 23, 2026 and 1.0% above the low. ACIU is down 37.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.0%.
AC Immune SA has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About AC Immune SA
Company profileAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Martin Zugel M.D., Ph.D.
- Headquarters
- Lausanne
- Employees
- 90
- IPO year
- 2016
- Website
- acimmune.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$8.41+331.28%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.16 vs $-0.22
- Surprise
- +27.27%
ACIU news
All ACIU news- FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer DrugNasdaqAZN, ADPT, SMMT, ACIU
- Sanofi's Next-Generation Rabies Vaccine Secures Approval in EUNasdaqSNY, ADPT, ACIU, AMRX
- SNY Wins FDA Approval for Infilbray in Type 3 Gaucher DiseaseNasdaqSNY, ADPT, ACIU, AMRX
- GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung CancerNasdaqGSK, ADPT, ACIU, AMRX
- Summit Stock Falls on FDA Rejection for Lung Cancer DrugNasdaqSMMT, ADPT, ACIU, AMRX
- Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusNasdaqKOD, REGN, ACIU, AMRX
- REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline ProgressNasdaqREPL, BMY, ADPT, ACIU
- Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch ReliefNasdaqZTS, ADPT, ACIU, AMRX
AC Immune SA peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANTXAN2 Therapeutics Inc. | 5.08 | -2.68% | $192.75M | vs ACIU |
| YARWYarrow Bioscience Inc. | 12.90 | -9.35% | $196.53M | vs ACIU |
| BIOABioAge Labs Inc. | 4.28 | -9.13% | $196.67M | vs ACIU |
| NGENNervGen Pharma Corp. | 1.85 | -3.91% | $198.55M | vs ACIU |
| RNACCartesian Therapeutics Inc. | 6.14 | +4.24% | $187.29M | vs ACIU |
| DRUGBright Minds Biosciences Inc. | 20.40 | -1.45% | $201.23M | vs ACIU |
| BCYCBicycle Therapeutics plc ADR | 2.90 | -4.92% | $203.27M | vs ACIU |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs ACIU |
Indexes, lists and sector
AC Immune SA stock FAQ
What is AC Immune SA's stock price today?
ACIU last traded at $1.95 as of Nov 20, 4:00 PM EST, down 8.45% on the day. Prices are delayed at least 15 minutes.
Who is AC Immune SA's CEO?
Dr. Martin Zugel M.D., Ph.D. is the chief executive officer of AC Immune SA, which has about 90 employees.
What is the ACIU 52-week high?
The 52-week high for ACIU is $3.90 and the 52-week low is $1.93. The stock is currently 50.0% below its high.